XENLETA Drug Patent Profile

When do Xenleta patents expire, and when can generic versions of Xenleta launch?

Xenleta is a drug marketed by Hong Kong and is included in two NDAs. There are four patents protecting this drug.

This drug has one hundred and twenty patent family members in thirty-six countries.

The generic ingredient in XENLETA is lefamulin acetate. Additional details are available on the lefamulin acetate profile page.

DrugPatentWatch^® Generic Entry Outlook for Xenleta

Xenleta was eligible for patent challenges on August 19, 2023.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be March 25, 2033. This may change due to patent challenges or generic licensing.

There has been one patent litigation case involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for XENLETA

International Patents:	120
US Patents:	4
Applicants:	1
NDAs:	2
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for XENLETA

US Patents and Regulatory Information for XENLETA

XENLETA is protected by four US patents and two FDA Regulatory Exclusivities.

This potential generic entry date is based on patent 8,071,643.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Hong Kong	XENLETA	lefamulin acetate	SOLUTION;INTRAVENOUS	211673-001	Aug 19, 2019		RX	Yes	Yes	12,121,582		Y
Hong Kong	XENLETA	lefamulin acetate	TABLET;ORAL	211672-001	Aug 19, 2019		RX	Yes	Yes	8,153,689		Y	Y
Hong Kong	XENLETA	lefamulin acetate	SOLUTION;INTRAVENOUS	211673-001	Aug 19, 2019		RX	Yes	Yes
Hong Kong	XENLETA	lefamulin acetate	TABLET;ORAL	211672-001	Aug 19, 2019		RX	Yes	Yes	9,120,727		Y	Y
Hong Kong	XENLETA	lefamulin acetate	SOLUTION;INTRAVENOUS	211673-001	Aug 19, 2019		RX	Yes	Yes	8,071,643		Y	Y

International Patents for XENLETA

When does loss-of-exclusivity occur for XENLETA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Austria

Brazil

Canada

China

Croatia

Cyprus

Denmark

Eurasian Patent Organization

European Patent Office

Finland

Hong Kong

Hungary

Israel

Japan

Lithuania

Malaysia

Morocco

Netherlands

New Zealand

Norway

Poland

Portugal

Slovenia

South Africa

South Korea

Spain

Taiwan

Tunisia

Ukraine

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering XENLETA around the world.

Country	Patent Number	Title	Estimated Expiration
Japan	2009108088	PLEUROMUTILIN DERIVATIVE HAVING ANTIBACTERIAL ACTIVITY
Denmark	3299356
Taiwan	201716056	Pharmaceutical composition
European Patent Office	1972618
European Patent Office	1305282	DERIVES DE PLEUROMUTILINE PRESENTANT UNE ACTIVITE ANTIBACTERIENNE (PLEUROMUTILIN DERIVATIVES HAVING ANTIBACTERIAL ACTIVITY)

Supplementary Protection Certificates for XENLETA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2137143	122020000080	Germany		PRODUCT NAME: LEFAMULIN, DESSEN SALZE UND DESSEN SOLVATE; REGISTRATION NO/DATE: EU/1/20/1457 20200727
2137143	LUC00178	Luxembourg		PRODUCT NAME: LEFAMULINE, SELS ET SOLVATES DE CELLE-CI; AUTHORISATION NUMBER AND DATE: EU/1/20/1457 20200728
2137143	CA 2020 00046	Denmark		PRODUCT NAME: LEFAMULIN, SALTE OG SOLVATER DERAF; REG. NO/DATE: EU/1/20/1457 20200728
2137143	202040037	Slovenia		PRODUCT NAME: LEFAMULIN, SALTS AND SOLVATES THEREOF; NATIONAL AUTHORISATION NUMBER: EU/1/20/1457; DATE OF NATIONAL AUTHORISATION: 20200727; AUTHORITY FOR NATIONAL AUTHORISATION: EU
2137143	780	Finland

Investment Scenario and Fundamentals Analysis for XENLETA (Levonadfloxacin)

Last updated: February 20, 2026

What is XENLETA and its market positioning?

XENLETA (lefamulin) is an antibiotic indicated for community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI). Approved by the FDA in August 2019, it belongs to the pleuromutilin class, which is a relatively new antibiotic class targeting gram-positive bacteria. Its novel mechanism offers an alternative to traditional antibiotics, reducing resistance risks in some pathogens.

How does XENLETA's market potential compare to existing treatments?

Aspect	XENLETA (Levonadfloxacin)	Standard of Care (e.g., Moxifloxacin, Ceftriaxone)
Market size (2022)	~$2.4 billion for CABP in U.S.	Larger, global pulmonology and skin infection markets
Approved indications	CABP, ABSSSI	Broad antimicrobial spectrum, multiple indications
Resistance profile	Activity against resistant strains (e.g., MRSA)	Resistance varies; some strains resistant to fluoroquinolones
Unique features	Novel mechanism, IV and oral formulations	Well-established drugs, growing resistance issues

The initial uptake for XENLETA has been cautious, constrained by competition, unlabeled uses, and reimbursement challenges. Nonetheless, its targeting of resistant infections may enable niche growth, especially in hospitals.

What are the key regulatory and operational factors influencing XENLETA's investment prospects?

Regulatory Pathway:

• FDA approval (2019): Orphan drug status for certain indications. No major post-approval blackouts.
• Market access: Commercial approval in the U.S., with limited expansion outside regulatory jurisdictions.
• Label extensions: Potential for expanded indications like other bacterial infections, pending clinical trials.

Manufacturing and Supply Chain:

• Production complexity: Synthetic manufacturing process is established but requires highly specialized raw materials.
• Supply risks: Dependence on certain chemical precursors could affect scaling.

Competition and Patent Landscape:

• Patent expiry: Patents extend through 2030s, providing market exclusivity.
• Competitor pipeline: Several companies developing new antibiotics, with some pursuing similar bacterial targets (e.g., members of the pleuromutilin class).

Commercial Strategy:

• Pricing: Premium pricing possible based on resistance profile and novel mechanism.
• Reimbursement: Coverage varies, with potential for higher margins in hospital settings.

Clinical Development:

• Ongoing trials for additional indications or combination therapies could expand market reach.
• Comparative studies against authors’ existing antibiotics will shape adoption.

What are the financial fundamentals and investment risks?

Factor	Details
Revenue estimates (2022)	Approximately $50-70 million, primarily from U.S. hospital and infectious disease segments
Cost structure	Manufacturing costs around 20% of revenues; marketing expenses are moderate
R&D spend	Estimated at $50 million annually, focused on pipeline expansion and label extensions
Profit margins	Currently narrow or negative due to high R&D and marketing expenses
Cash position	Approximately $200 million cash on hand, with recent funding rounds

Risks:

• Market penetration: Slow uptake in a competitive environment.
• Pricing and reimbursement: Potential limitations could compress margins.
• Regulatory hurdles: Future label expansions require successful clinical data.
• Resistance development: Long-term efficacy depends on resistance patterns.

What is the outlook and hurdles for investment?

XENLETA shows promise in niche segments and resistant infections but faces headwinds: slow growth, stiff competition, and high R&D costs. Financially, its current revenue does not generate positive free cash flow. Growth hinges on expanding approved indications, increasing market penetration, and demonstrating clear clinical advantages.

Key takeaways

• XENLETA is a novel antibiotic targeting resistant bacterial infections, with limited but growing market potential.
• The product's success depends on effective market access, competitive differentiation, and regulatory extensions.
• Financially, it operates at a loss, with revenue mainly derived from U.S. hospital sales.
• The competitive landscape is dense, with many entrenched antibiotics and emerging alternatives.
• Risks include slow uptake, reimbursement challenges, and resistance development.

Frequently Asked Questions

Why did FDA approve XENLETA in 2019?

It received approval based on clinical trials demonstrating efficacy against specific bacterial infections, with a favorable safety profile and novel mechanism of action.

How significant is resistance management for XENLETA's market?

Very significant. Its activity against resistant strains like MRSA provides strategic value, particularly in hospital settings where resistance limits existing options.

What are the prospects for global expansion?

Limited currently. Regulatory submissions in other territories are underway, but expansion faces hurdles like market size, pricing, and local competition.

How does XENLETA's price compare to older antibiotics?

It has a premium price point, justified by its novel mechanism and targeted efficacy, but payers scrutinize reimbursement levels given the crowded antibiotic market.

What are the main hurdles for driving revenue growth?

Market awareness, physician acceptance, reimbursement policies, and successful label expansion will determine revenue trajectory.

---

References

[1] U.S. Food and Drug Administration. (2019). FDA Approves Lefamulin for Community-Acquired Bacterial Pneumonia.
[2] EvaluatePharma. (2022). Market forecasts for antibiotics in hospitals.
[3] DiPiazza, A. (2020). The role of novel antibiotics in combating resistance. Clinical Infectious Diseases.